Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sabin Inactivated Poliovirus Vaccine in Infants
NCT03902054Phase 2Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Dec 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (5 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Seroconversion rates (SCRs), Post-immune geometric mean titer (GMT) and 1 more. Started Dec 2017; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT03902054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902054.